Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
CNS Drug Liabilities in Early Phase Clinical TrialsPublished: May 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
2
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
3
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
4
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
5